Key Takeaways
- Subdued quarter, tender-driven: Sales volume stayed soft as Rifa-S offtake, roughly 50% of the business, fell sharply on delayed government and global TB tenders. Management kept producing into inventory, betting the tenders open soon.
- 9M performance already ahead of full-year FY22: Revenue and profit for the first nine months surpassed the entire prior fiscal year, despite the Q3 sales dip, underscoring the underlying strength in Rifamycin-O and the lumpiness of the tender cycle.
- Capex build-out on track: INR 14 crores spent of the INR 200 crore plan, with the API block expected up and running by June-July 2023 and R&D labs coming online in phases through November 2023.
- Margins compressed by R&D investment: EBITDA margin fell 966 bps YoY, driven almost entirely by ~INR 2.44 crores in R&D expenditure, a deliberate spend to seed the next leg of growth.
- What to watch next quarter: Whether the anticipated TB tenders actually open and convert the built-up Rifa-S inventory into revenue, and whether the API block commissioning stays on its June-July timeline.
The Rifa-S Tender Overhang
- The core drag: Rifa-S is a tender-driven anti-TB intermediate, and offtake was significantly lower because government and global tuberculosis tenders were delayed. This single product, roughly half the business, caused the quarter's sales softness.
- Inventory bet in motion: The company deliberately did not take a plant shutdown this year, unlike the last two years, and continued Rifa-S production to build inventory. Management sees this as a signal of its conviction that demand will materialize.
- No clean quarterly pattern: Q3 sales have declined over the last few years, but management has not identified a clear seasonal pattern and attributes the moves to the cycling of TB tenders. Year-on-year sales have still increased.
- The tender timeline: Management expects tenders to open over the next two quarters but will not speculate whether that means the current quarter or the one after. The visibility is directional, not dated.
Patel: "We are not stopping our production because we anticipate that as the tuberculosis tenders open up, the demand is going to be there, quite a significant demand is going to be there... the fact that we are not stopping production is an indicator that we believe this is very realistic."
Capex Program: API Block, R&D Labs & Fermentation
- API block: Expected to be up and running by June-July 2023, with all INR 40 crores of its budget spent by July 2023. It is a multipurpose facility designed to produce APIs from the company's own fermentation products plus independent synthetic APIs.
- R&D labs: Two sections under construction. The first is expected to start running June-July 2023, the second around November 2023. The build includes a CGMP pilot facility for scale-up, regulatory filings and stability studies before commercial-block operations.
- Fermentation block: Additional fermentation capacity is expected by June-July of the next financial year (FY24), with trial batches and production to begin after that. Management says it is too early to specify which products or the market size.
- Commercialization cadence: From the API block, some products should be commercializable 6 to 9 months after the June-July 2023 completion. The fermentation block's products are further out, with commercialization timelines still undefined.
- Product selection discipline: Management stressed it scrutinizes gross margins carefully for new-facility products because the new assets carry significant depreciation versus the old, fully depreciated facility. The goal is healthy bottom lines, not just volume.
Patel: "We need to be very, very careful in terms of the products that we select, so as to make sure that we have healthy bottom-lines which are much required to sustain this kind of business."
R&D Investment & Margin Impact
- The margin math: The 966 bps YoY EBITDA margin decline was driven by R&D expenditure of approximately INR 2.44 crores. The cost structure shift is partly R&D and partly the nature of the tender-driven product mix.
- R&D team build: One foreign consultant has been hired full-time in the plant R&D, two more foreign consultants are advising offline, and one senior Indian consultant has been engaged for future endeavors. The intention is to keep growing the team.
- Expense trajectory unclear: Management said it is very difficult to comment on how R&D expenses will trend as a percentage of sales. Material cost in fermentation is not expected to be very high, so the variable is people cost.
- One near-term API candidate: Management flagged at least one API product with significant potential in the very near future, describing it as something expected to change current therapy, with the company positioned to be among the first few to launch in India and elsewhere.
Patel: "I believe that one, at least one product would have a significant potential in the very near future because it is something that is expected to change the current therapy, and we'll be one of the first few of the companies to launch this particular product in India and elsewhere too."
Margin Structure & Forward Integration
- Fermentation vs forward integration: Management was explicit that forward-integration margins will not be as healthy as fermentation margins because more companies operate in that space. The strategic rationale is business control, not margin maximization.
- API margin expectations: On the synthetic API pipeline, management expects better margins than the typical ~17% seen in the industry, though it did not quantify the premium.
- Capex strategy is ROI-led, not revenue-led: Management declined to provide turnover expectations for the INR 200 crore capex plan, stating the objective is to minimize the number of years for ROI payback. Current ROI is described as "pretty, pretty healthy," and achieving something similar for the new facility would be satisfactory.
- Pricing independence from China: The company sets contracts based on its own costing and margin expectations plus those of its partners, and does not benchmark against Chinese prices.
Patel: "If we are moving into forward integration I don't believe that the margins would be as healthy as they are in fermentation, because the minute you are moving into forward integration there are significant number of companies that are doing the same thing."
Capacity Utilization & Production
- Full-capacity plan: The plan for the current year is to run production capacity at 100%, up from a historical 75%. This reflects both the inventory-build strategy for Rifa-S and sustained demand for Rifamycin-O.
- Rifamycin-O strength: Demand for Rifamycin-O continues with sufficient uptick, providing a stable counterweight to the lumpy Rifa-S tender cycle.
- Fermentation capability limits: Management cautioned against assuming the company can produce anything via fermentation, calling that a tall task and stating it would be incorrect to claim it can produce everything. Product selection is deliberate and capability-constrained.
Patel: "I would honestly say that it's a case-to-case basis because if we feel that we can produce anything in fermentation just because we do fermentation I think it could be at tall task. It would be incorrect for us to state that we can produce everything under the earth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Tender-driven volume recovery | Significant increase in Rifa-S volumes when TB tenders open | Over the next two quarters |
| API block operational | Facility up and running; all INR 40 crores spent | June-July 2023 |
| R&D labs operational | First section running; second section running | June-July 2023; ~November 2023 |
| API block commercialization | Some products commercializable 6-9 months post-completion | ~Jan-April 2024 |
| Fermentation block capacity | Additional capacity available; trial batches begin | June-July FY24 |
| Revenue growth | 25% to 30% growth, which the API block should help attain | Next financial year |
| Production utilization | Run at 100% capacity vs 75% historically | Current year |
| API regulatory filings | Filings in regulated markets (if not US, at least some) with orders expected | Next financial year |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹28.2 cr, 51.4% YoY rise |
| 9M FY23 revenue | ₹120.8 cr, already surpassed full FY22 revenue |
| EBITDA | ₹12.1 cr, 23.6% YoY increase |
| EBITDA margin | 43%, down 966 bps YoY |
| R&D expenditure | ₹2.44 cr, had a bearing on profit margins |
| PAT | ₹9.8 cr, vs ₹7.1 cr in Q3 FY22 |
| Net profit margin | 34.8% |
| EPS | ₹6.75 |
| Revenue growth target for next financial year | 25% to 30%, API block expected to help attain this |
| Production capacity utilization plan for FY23 | 100%, up from 75% in the last two years |
| Capex plan | ₹200 cr over next 2–3 years |
| Capex spent so far | ₹14 cr |
| CWIP | ₹13 cr |
| API block capex | ₹40 cr out of ₹80 cr Phase 1, all to be spent by July |
| Average power consumption | ~3 megawatt peak load, uniformly used |
| Gross margin over material cost for API block | 40% to 50% |